CDC Vaccine Review Sparks Controversy Over Thimerosal Study Citation 
Neuren Pharmaceuticals Surges on U.S. Patent Win for Rare Disorder Drug 
Asian Currencies Steady as Fed Delivers Hawkish Rate Cut; Aussie and Rupee Under Pressure 
Asian Currencies Hold Steady as Indian Rupee Slides to Record Low on Fed Outlook 
Moore Threads Stock Slides After Risk Warning Despite 600% Surge Since IPO 
Air Transat Reaches Tentative Agreement With Pilots, Avoids Strike and Restores Normal Operations 
Trump’s Approval of AI Chip Sales to China Triggers Bipartisan National Security Concerns 
SpaceX Starship Test Flight Reaches New Heights but Ends in Setback 
China Adds Domestic AI Chips to Government Procurement List as U.S. Considers Easing Nvidia Export Curbs 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
NASA Partners with Katalyst to Save Swift Observatory with Innovative Docking Mission 
Japan Weighs New Tax Breaks to Boost Corporate Investment Amid Spending Debate 
ADB Approves $400 Million Loan to Boost Ease of Doing Business in the Philippines 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Evercore Reaffirms Alphabet’s Search Dominance as AI Competition Intensifies 
A team of Japanese scientists has developed a method that utilizes glucose and fragmented antibodies in reducing an abnormal accumulation of protein in the brains of mice with Alzheimer’s disease.
According to Takanori Yokota, a neurology professor at the university who was part of the team, they hope accomplishment will lead to the development of a new therapy that is safer and more efficient than its conventional antibody-used counterpart.
The amyloid beta protein accumulation in the brain is believed to trigger Alzheimer’s.
The researchers, primarily from Tokyo Medical and Dental University and the Innovation Center of Nanomedicine (iCONM), encapsulated fragments of an antibody that can attach itself to the protein and remove it from the brain into a so-called nanomachine.
They also attached glucose molecules to the nanomachine's surface, making it simpler for the brain to receive the antibody.
The mice with abnormally high levels of amyloid beta due to the disease were given injections of the encapsulated antibody fragments by the researchers. The agent was administered weekly for 10 weeks.
In contrast to just injecting them there, the study found that employing a nanomachine can deliver 80 times more antibody fragments to the brain.
It was also established that this technique can be used to get rid of amyloid beta lumps, which prevented the protein from gathering.
Because a whole antibody is too large to be placed in many places, the researchers chose to employ antibody fragments instead.
The result was a positive effect that was unanticipated.
Historically, the blood-brain barrier, which determines what to take in from blood vessels to protect the brain, prevented the entire prescribed medication to eliminate the protein from reaching the brain.
Therapeutic antibodies for Alzheimer's disease are well known for having undesirable side effects, such as inflamed brain swelling.
As the fragmented antibody lacks the portion that causes inflammatory reactions, the team anticipates that this side effect may be avoided.
